Sobell, Jeffrey M., Boni Elewski, Subhashis Banerjee, Eugene Balagula, Thomas Scharnitz, Victoria Berger, Kim Hoyt, Paul Yamauchi, Miriam Bettencourt, Michael C. Cameron, and Mark Lebwohl. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s238. Accessed July 15, 2024. https://www.jofskin.org/index.php/skin/article/view/2355.